Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Alexion Pharmaceuticals history
Alexion Pharmaceuticals company history timeline
Alexion Pharmaceuticals, established in 1992, is a renowned global biopharmaceuticals company best known for its Soliris drug used for the treatment of rare disorders such as atypical hemolytic uremic syndrome (aHUS). It has been in the forefront of research into autoimmune diseases.
Alexion Pharmaceuticals was founded by Leonard Bell in 1992 at Science Park in New Haven, Connecticut.
1993 – C5 complement inhibitor development program commences.
1994 – First pilot manufacturing facility established in New Haven, CT, USA.
1996 – Initial public offering on NASDAQ under ticker symbol ALXN.
1998 – First in-human clinical trial of eculizumab begins,
In 2000, it purchased Proliferon Inc, a development stage biopharmaceutical firm based in California for us $41 mn in Alexion stock.
2002 – Pilot study with eculizumab commenced in Leeds, England in paroxysmal nocturnal hemoglobinuria (PNH).
2004 – Positive results from the pilot study with eculizumab in 11 patients with PNH published in the New England Journal of Medicine.
The European office was started in 2005.
2005 – Alexion Europe SAS established in Paris, FranceSecond pivotal Phase 3 study of eculizumab in patients with PNH (SHEPHERD) begins.
2006 – Biomanufacturing facility in Smithfield, RI, USA, acquired in anticipation of commercial-scale production of eculizumab.
2006 – Clinical data from the TRIUMPH PNH study published in the New England Journal of Medicine.
2007 – Soliris® approved by the FDA and European Medicines Agency as the first and only treatment for patients with PNH.
2008 – Soliris first as a treatment for patients with atypical hemolytic uremic syndrome (aHUS) in France and GermanySoliris awarded Prix Galien USA Award for Best Biotechnology Product with Broad Implications for Future Biomedical Research.
2009 – Soliris awarded the Prix Galien France Award for Drugs for Rare DiseasesAlexion’s Rhode Island manufacturing facility receives EU approval to supply Soliris.
In June 2010, there was an outbreak of hemolytic-uremic syndrome caused by Shigatoxigenic and verotoxigenic Escherichia coli (EHEC) in Germany.
In 2011, it acquired Enobia Pharma Corp, which is based in Montreal, Canada.
2011 – Alexion responds to a historic public health crisis in Germany and provides Soliris® without charge to hundreds of patients with life-threatening Shiga toxin E-coli-related hemolytic uremic syndrome (STEC-HUS).
In January 2014, the company paid Moderna $100 million for ten product options to develop rare disease treatments, including for Crigler-Najjar syndrome, using Moderna's mRNA therapeutics platform.
In April 2015, Bell was replaced as CEO by David Hallal.
In June 2015, Alexion acquired Synageva, a maker of rare disease treatments, in an $8.4 billion stock-and-cash deal.
Alexion moved its headquarters back to New Haven following the completion of New Haven's Downtown Crossing project in February 2016.
In December 2016, David Brennan became interim CEO. David Anderson, formerly the CFO of Honeywell, was appointed CFO, replacing Vikas Sinha.
In April 2018, Alexion announced the acquisition of Wilson Therapeutics for $855 million.
In July 2020, the company agreed to pay more than $21 million to settle claims that it bribed government officials in Turkey and Russia to gain approval for its drugs.
In July 2021, AstraZeneca acquired the company.
Rate Alexion Pharmaceuticals' efforts to communicate its history to employees.
Alexion Pharmaceuticals jobs
Do you work at Alexion Pharmaceuticals?
Is Alexion Pharmaceuticals' vision a big part of strategic planning?
Alexion Pharmaceuticals competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Regeneron | 1988 | $14.2B | 9,123 | 310 |
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 294 |
| Sunovion Pharmaceuticals | 1984 | $600.0M | 2,400 | 19 |
| Pfizer | 1849 | $63.6B | 78,500 | 580 |
| Octagon Research Solutions | 1999 | $1.1M | 50 | - |
| Shire Pharmaceuticals Inc | 2004 | $15.2B | 3,500 | - |
| Cyberonics | 1987 | $291.6M | 660 | - |
| Nanotherapeutics, Inc. | - | - | - | - |
| Incyte | 1991 | $4.2B | 1,600 | 37 |
| Azzur Group | 2010 | $3.0M | 266 | - |
Alexion Pharmaceuticals history FAQs
Zippia gives an in-depth look into the details of Alexion Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Alexion Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Alexion Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Alexion Pharmaceuticals. The data presented on this page does not represent the view of Alexion Pharmaceuticals and its employees or that of Zippia.
Alexion Pharmaceuticals may also be known as or be related to Alexion, Alexion Pharmaceuticals, Alexion Pharmaceuticals Inc, Alexion Pharmaceuticals Inc. and Alexion Pharmaceuticals, Inc.